Holen Sie sich die Stockscreener-App
21.01
2.73%
-0.59
Schlusskurs vom Vortag:
$21.60
Offen:
$21.57
24-Stunden-Volumen:
212.46K
Relative Volume:
0.57
Marktkapitalisierung:
$637.23M
Einnahmen:
$344.23M
Nettoeinkommen (Verlust:
$-24.16M
KGV:
-24.80
EPS:
-0.8471
Netto-Cashflow:
$28.33M
1W Leistung:
-0.33%
1M Leistung:
-14.59%
6M Leistung:
-45.63%
1J Leistung:
+23.44%
1-Tages-Spanne:
$20.99
$21.78
1-Wochen-Bereich:
$19.51
$21.84
52-Wochen-Spanne:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
21.01 | 655.13M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth - Investing.com
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised - Investing.com
Castle Biosciences (CSTL) CEO sells shares and exercises options under 10b5-1 plan - Stock Titan
CSTL: Raised 2026 guidance after strong Q1 growth and expanded diagnostic test adoption - TradingView
CSTL: Raised 2026 revenue guidance on strong test growth and innovation in dermatology and GI - TradingView
Trading the Move, Not the Narrative: (CSTL) Edition - Stock Traders Daily
Maetzold-related trusts sell shares (CSTL) in multiple Form 144 trades - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant - Stock Titan
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units - Stock Titan
Director at Castle Biosciences (CSTL) granted 11,766 RSUs - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSU compensation award - Stock Titan
Director at Castle Biosciences (CSTL) receives 11,766 RSU equity award - Stock Titan
Castle Biosciences (NASDAQ: CSTL) grants 11,766 RSUs to director - Stock Titan
Is Castle Biosciences Inc (CSTL) a Bargain After 4.7% Drop? GF V - GuruFocus
Castle Biosciences (NASDAQ: CSTL) investors approve directors, pay and KPMG - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Downgraded by Zacks Research to "Hold" - MarketBeat
Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know - MSN
Castle Biosciences (CSTL) director receives 13,667 shares via RSUs - Stock Titan
Director Daniel Bradbury adds 13,667 CSTL shares via RSU exercise, boosts direct and trust holdings - Stock Titan
Castle Biosciences (CSTL) director converts 13,667 RSUs into common shares - Stock Titan
Director at Castle Biosciences (CSTL) settles 13,667 RSUs into common stock - Stock Titan
Director at Castle Biosciences (NASDAQ: CSTL) converts 13,667 RSUs to shares - Stock Titan
Director at Castle Biosciences (CSTL) gains 13,667 shares via RSU exercise - Stock Titan
Castle Biosciences (CSTL) director converts 13,667 RSUs into Common Stock - Stock Titan
Castle Biosciences (CSTL) CCO exercises options to add 11,210 shares - Stock Titan
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets - Yahoo Finance
(CSTL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Castle Biosciences (CSTL) CEO reports planned stock sales and option exercises - Stock Titan
Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - MSN
Castle Biosciences, Inc. $CSTL Shares Sold by UBS Group AG - MarketBeat
Portolan Capital amends Castle Biosciences (NASDAQ: CSTL) 13G; 4.45% stake reported - Stock Titan
RTW Funds own 2.76M Castle Biosciences shares (CSTL) — 9.3% stake - Stock Titan
A Look at Castle Biosciences Inc (CSTL) After 4.1% Gain -- GF Va - GuruFocus
Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon - Investing.com
Castle Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-05-13 - Seeking Alpha
META_TITLE_QUOTE - Yahoo Finance
CSTL Maintained by BTIG -- Price Target Lowered to $40.00 - GuruFocus
BTIG lowers Castle Biosciences stock price target on higher costs By Investing.com - Investing.com India
BTIG Research Has Lowered Expectations for Castle Biosciences (NASDAQ:CSTL) Stock Price - MarketBeat
BTIG lowers Castle Biosciences stock price target on higher costs - Investing.com UK
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference - PR Newswire
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Bre - GuruFocus
Castle Biosciences recognized for driving progress in global healthcare with AdvanceAD-Tx accolade - Traders Union
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation - PR Newswire
Price-Driven Insight from (CSTL) for Rule-Based Strategy - Stock Traders Daily
TradingKey - TradingKey
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares By Investing.com - Investing.com Australia
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares - Investing.com India
Castle Biosciences (CSTL) CEO sells shares and exercises stock options in pre-planned trades - Stock Titan
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):